NCT06800885 (Vakzimeter FLU) is a clinical trial in Influenza Immunization, sponsored by Sanofi Pasteur, a Sanofi Company.

Who is sponsoring NCT06800885?

NCT06800885 is sponsored by Sanofi Pasteur, a Sanofi Company.

What condition does NCT06800885 study?

NCT06800885 studies Influenza Immunization.

Is NCT06800885 still recruiting?

NCT06800885 is currently completed. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT06800885: Vakzimeter FLU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants

Completed Last updated 5 March 2026

What this trial tests

trial in Influenza Immunization in 5,000 participants. Completed in 22 February 2026.

Timeline

22 October 2024

Primary endpoint
22 February 2026

22 February 2026

Quick facts

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	22 October 2024
Primary completion	22 February 2026
Estimated completion	22 February 2026
Sites	1 location across Germany

Conditions studied

Influenza Immunization — all drugs for Influenza Immunization →

Sponsor

Sanofi Pasteur, a Sanofi Company — full company profile →

Who can join

18 and older, any sex, with Influenza Immunization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage. This study aims to address the gap by assessing current influenza vaccination rates, particularly among those aged 60 and older, to inform public health interventions and encourage healthcare providers to recommend influenza vaccination more proactively. The primary objective of this study is to determine the influenza vaccination rates in the German population during the current respiratory season. The study will focus on: 1. Assessing the vaccination rates among the two main age groups 18 years of age through and including 59 years of age and 60 years of age (inclusive) and older 2. Assessing the vaccination rate among individuals with risk-based vaccination recommendation according to Standing Committee on Vaccination (Ständige Impfkommission) (STIKO) The study will target a disproportionate sample of the German population regarding age: 30% aged 18 years of age through and including 59 year of age and 70% aged 60 years of age (inclusive) and older. Within these age groups, the study targets a representative distribution regarding gender and region. This study is conducted as an online survey that will either be self-completed by the respondents (CAWI) or completed via an interviewer for a subgroup of respondents aged 70+ (CATI). The survey is estimated to last 10 minutes and will comprise of closed-ended questions only (i.e., respondents will not have the possibility to add any free-text). The survey will be conducted in German. The panelists will be divided into strata based on demographic variables like gender and region. Within each stratum, participants will be randomly selected to participate in the survey.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Influenza Immunization

Currently open trials in the same condition.

NCT06727058 — Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older · Phase 1, PHASE2 · active not recruiting
NCT06695117 — Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombin · Phase 1, PHASE2 · active not recruiting
NCT06695130 — Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombin · Phase 1, PHASE2 · active not recruiting

Other Sanofi Pasteur, a Sanofi Company trials

Trials by the same sponsor.

NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06800885 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06800885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing